Inovio Pharmaceuticals, Inc. (INO) Earnings Call Transcripts

Inovio Pharmaceuticals, Inc.'s Latest Earnings Call - June 4, 2026

Inovio Pharmaceuticals' Q2 2026 earnings call highlighted significant developments for their lead candidate, 3107, aimed at treating recurrent respiratory papillomatosis (RRP). The company reported that their Biologics License Application (BLA) for 3107 is under FDA review with a PDUFA date set for October 30, 2026. Revenue and earnings figures were not disclosed, and no changes to financial guidance were mentioned. The focus was on the regulatory pathway and the potential market impact of 3107, which has shown promising efficacy in reducing surgeries for RRP patients. Management is optimistic about securing accelerated approval despite preliminary FDA concerns.

Reported metrics

Guidance from management

Inovio is focused on securing accelerated approval for 3107 and advancing its clinical pipeline. They are preparing for a potential U.S. launch post-approval and seeking partnerships for international markets.

What management said

Yes. Since I mentioned, we've been very happy generally with how our review has been progressing. Clearly, we still need to get this informal meeting to discuss the review pathway in place. And we really can't comment at this time on changes in leadership. There have clearly been a lot of changes over the past few months. And we're encouraged by the signs that we're seeing from the new leadership. And we look forward...

Yes, great questions. So we have submitted an amendment to our IND for our confirmatory trial. We have about 20 clinical sites up and ready to start that confirmatory trial. Once FDA gets back to us on the protocol. But until FDA gets back to us on the protocol, I don't think I can really comment on the design of the trial.

What analysts pressed on

Analysts expressed concerns about the FDA's preliminary comments on the accelerated approval pathway for 3107 and the potential impact of regulatory changes. There were also questions about the confirmatory study and its alignment with the PDUFA timeline.

Main topics on the call

• Regulatory Pathway for 3107 — Inovio's BLA for 3107 is under FDA review with a PDUFA date of October 30, 2026. The FDA raised preliminary concerns about eligibility for accelerated approval, but Inovio is confident in meeting the criteria, citing 'me...
• Efficacy of 3107 — 3107 demonstrated a 72% reduction in surgeries for patients in year one, increasing to 86% in year two. 28% of patients required no surgeries in year one, rising to 50% in year two. This efficacy is a key differentiator ...
• Manufacturing and Commercialization Plans — Inovio has established commercial-scale manufacturing for 3107 and plans to launch the drug in the U.S. using a contract sales organization. They are exploring partnerships for ex-U.S. commercialization.
• Pipeline Developments — Inovio's pipeline includes VGX-3100 in Phase III, with positive top-line data reported, and 5412 for glioblastoma, which will combine with a dual checkpoint inhibitor in an upcoming trial.

Read the full Inovio Pharmaceuticals, Inc. transcript (June 4, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 37 Inovio Pharmaceuticals, Inc. earnings call transcripts on record, spanning March 12, 2020 to August 12, 2026. Based on this history, Inovio Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated August 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

INO

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

37

First call

March 12, 2020

Most recent

August 12, 2026

Reporting cadence

quarterly